The federal government notified drug makers on Friday about its withdrawal of its 340B contract pharmacy legal advisory opinion. | Shutterstock

Government Notifies Drug Companies About 340B Contract Pharmacy Advisory Opinion’s Withdrawal

The federal government notified drug makers Lilly, Novo Nordisk, and Sanofi in court papers on Friday about its withdrawal of its 340B contract pharmacy legal advisory opinion, in connection with AstraZeneca’s contract pharmacy lawsuit. It said the withdrawal does not affect enforcement proceedings against them for denying 340B pricing on drugs when covered entities use contract pharmacies.

Last week Wednesday, the federal judge hearing AstraZeneca’s suit ruled that the 340B statute is silent on contract pharmacy. The government responded on Friday by withdrawing the advisory opinion.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
×

Sign up for news summaries and alerts from 340B Report